Why Omeros Shares Soared

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biopharmaceutical company Omeros surged 15% today after announcing that the New Drug Application, or NDA, for its experimental eye-surgery drug, OMS302, has been confirmed for filing by U.S. and European regulators.

So what: The stock has soared in 2013 on growing enthusiasm for OMS302, and today's news only reinforces the notion that it does fulfill an unmet medical need. In fact, Wedbush analyst Liana Moussatos recently noted that OMS302 would be the only treatment combining pain relief and pupil dilation that also met the FDA's new replacement surgery requirements, giving investors plenty of good vibes over the drug's blockbuster potential.

Now what: Analysts expect the FDA to make an approval decision on OMS302 in the middle of next year.

"The acceptance for filing of our NDA by the FDA and validation of our MAA by the EMA mark important milestones on the path toward the commercial launch of OMS302 expected in 2014," said Chairman and CEO Gregory Demopulos.

So while the stock might be too hot and risky for average investors, biotech-savvy Fools might want to take a closer look at Omeros' seemingly bright prospects.

Even healthier health care picks
Obamacare is rewriting the rules for the health care industry, and in the process of doing so, it's creating massive opportunities for investors to get ridiculously rich. How? By investing in a handful of specific health care stocks. In this free report, our analysts walk you through these opportunities and the companies that are positioned to exploit them. The informational edge contained in it is invaluable, but can only be exploited profitably while the rest of the market remains in the dark. To access this free report instantly, simply click here now.

The article Why Omeros Shares Soared originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story